artu,Estonia and Salt Lake City,Utah,USA—March 20,2023—Icosagen Group,an established research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals,today announced that it has acquired the LSA®platform from Carterra®,a leading provider of high-throughput antibody screening and characterization solutions.
爱沙尼亚塔尔图和美国犹他州盐湖城——2023年3月20日——Icosagen Group是一家知名的研究驱动型组织，为哺乳动物细胞衍生生物制剂的发现和生产提供服务。今天，该公司宣布已从Carterra公司收购LSA®平台，Carterra是一家领先的高通量抗体筛选和表征解决方案提供商
Icosagen Cell Factory(ICF)has grown into a mammalian Contract Research,Development,and Manufacturing Organization(CRDMO)for biopharmaceutical,biotechnology,and diagnostic industries,and offers seamless discovery,development,and manufacturing of mammalian therapeutic antibodies.Services cover up to early clinical candidate development,including stable CHO cell line development for 50L to 1000L GMP production runs.In 2022,ICF worked with more than 100 protein drug or vaccine development companies globally,producing more than 3000 different proteins.The acquisition of the Carterra LSA technology will significantly enhance the flexibility and throughput of antibody screening and characterization.
Icosagen细胞工厂（ICF）已经发展成为一个哺乳动物合同研究、开发和制造组织（CRDMO），为生物制药、生物技术和诊断行业提供服务，并提供哺乳动物治疗抗体的无缝发现、开发和制造。服务范围涵盖早期临床候选药物开发，包括用于50L至1000L GMP生产线的稳定CHO细胞系开发。2022年，ICF与全球超过100家蛋白质药物或疫苗开发公司合作，生产了超过3000种不同的蛋白质。收购Carterra LSA技术将显著提高抗体筛选和表征的灵活性和吞吐量。
Carterra’s LSA will enable ICF to speed up and significantly enhance its end-to-end service capabilities for global biotechnology and pharmaceutical customers.ICF will also be able to offer automated workflows for their entire library of candidates by leveraging the LSA’s capture-based kinetics and affinity measurements,coupled kinetics,epitope binning,quantitation,epitope mapping,and blocking/neutralization assays.
Carterra的LSA将使ICF能够加速并显著提升其为全球生物技术和制药客户提供端到端服务的能力。ICF还将能够通过利用LSA的基于捕获的动力学和亲和力测量、耦合动力学、表位分组、定量、表位映射和阻断/中和测定，为其整个库中的候选者提供自动化工作流程。
“We are thrilled to be partnering with Carterra to integrate their cutting-edge LSA technology into our antibody discovery platform,”said Mart Ustav Jr.,Chief Scientific Officer of Icosagen.“This collaboration will speed our discovery and development efforts saving us time and significantly enhancing our antibody screening capabilities.We are extremely excited to work with Carterra on developing new workflows that support our unique antibody discovery capabilities.Our joint commitment is to advance the field of antibody discovery and to improve human health.”
“我们很高兴能与Carterra合作，将他们的尖端LSA技术整合到我们的抗体发现平台上，”Icosagen的首席科学官小马丁·乌斯塔夫说。“这次合作将加快我们的发现和开发工作，节省时间并显著提高我们的抗体筛选能力。我们非常兴奋能与Carterra合作开发支持我们独特抗体发现能力的新工作流程。我们的共同承诺是推进抗体发现领域的发展，改善人类健康。”
Carterra’s LSA®biosensor for antibody discovery and characterization was launched in 2018.The LSA combines patented microfluidics technology with real-time high-throughput Surface Plasmon Resonance(HT-SPR)and industry-leading data analysis and visualization software to revolutionize mAb screening.The release of the LSA set a new standard for high-throughput screening and characterization of antibodies and has been adopted as a standard in 19 of the 20 largest pharmaceutical companies,biotechs,CROs,academia,the NIH,and the FDA.Carterra’s LSA instrument,software,and consumables deliver up to 100 times the throughput of existing platforms in 10%of the time while using only 1%of the sample required by other systems.
Carterra的LSA®生物传感器用于抗体发现和表征，于2018年推出。LSA结合了专利的微流体技术与实时高通量表面等离子共振（HT-SPR）以及业内领先的数据分析和可视化软件，以彻底改变单克隆抗体的筛选。LSA的发布为抗体的高通量筛选和表征设定了新标准，已被20家最大的制药公司、生物技术公司、CRO、学术界、NIH和FDA中的19家采用。Carterra的LSA仪器、软件和耗材的吞吐量是现有平台的100倍，但所需时间仅为其他系统所需时间的10%，同时仅使用1%的样本。
“Icosagen’s vision for making drug discovery and development services faster and better is shared by all of us at Carterra,”said Tim Germann,Chief Commercial Officer at Carterra.“The LSA is a game-changing biologics discovery technology that has enabled rapid and high-definition characterization of entire antibody libraries.Icosagen joins the pace-setting group of researchers the world over deploying Carterra’s LSA to improve human health.”
Carterra首席商务官蒂姆·格曼（Tim Germann）表示：“Carterra的所有人都认同Icosagen的愿景，即让药物发现和开发服务更快、更好。LSA是一种革命性的生物发现技术，能够快速、高精度地描述整个抗体库。Icosagen加入了一个由世界各地的研究人员组成的团队，他们正在部署Carterra的LSA，以改善人类健康。”
